Business
BELLUS Health Announces Exploratory Results in Peer-Reviewed Publication Reveal Tramiprosate Slows Atrophy of Brain Hippocampus with Preliminary Evidence of Beneficial Effect on Cognition
Tramiprosate North American Phase III Clinical Study Results Published in Journal of Nutrition, H...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n Tramiprosate North American Phase III Clinical Study Results\n Published in Journal of Nutrition, Health and Aging\n\n\nLAVAL, QC, July 6 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) announces\nthat the Journal of Nutrition, Health and Aging, the journal of the European\nUnion Geriatric Medicine Society, has published results showing that\ntramiprosate (homotaurine) slows the loss of volume in the hippocampus, a\nregion of the brain associated with memory. These analyses also suggest that\ntramiprosate (homotaurine) has a beneficial effect on cognition. These\nanalyses were conducted on a subgroup of 312 patients that underwent Magnetic\nResonance Imaging (MRI) of the brain in the North American Phase III clinical\ntrial for tramiprosate for Alzheimer's disease (AD).\n\n\nThe Journal of Nutrition, Health and Aging is a peer-reviewed journal\nwhose aim is to contribute to the improvement of knowledge regarding the\nrelationships between nutrition and the aging process from birth to old age.\nThe article entitled, "Effect of Tramiprosate in Patients with\nMild-to-Moderate Alzheimer's Disease: Exploratory Analyses of the MRI\nSub-group of the Alphase Study," was published in the n 6, June 2009 issue of\nthe journal. An online version of the publication will be available at\nhttp://www.springerlink.com/content/1760-4788 in the next few days.\n\n\nThe efficacy, safety and disease-modification of tramiprosate\n(homotaurine) was investigated in a large-scale multi-center, double-blind,\nrandomized, placebo-controlled Phase III clinical study in 1,052 patients with\nmild-to-moderate AD. A subset of 508 patients underwent volumetric MRI\nmeasurements. Of these, 312 completed the 78-week trial and provided paired\nscans of their hippocampus volume changes at study entry and final visits, and\nwere included in these analyses. Patients were randomized to receive placebo\nBID, tramiprosate 100 mg BID, or tramiprosate 150 mg BID for 78 weeks.\nMulti-variable statistical models using accepted methods for covariate\nselection were developed to assess the treatment effect on standardized\nAlzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and\nClinical Dementia Rating-Sum-of-boxes (CDR-SB) assessments.\n\n\nResults\n\n\nThe analyses describe the hippocampal volume change and cognitive and\nclinical results in t...